Metabolic Characterization of All-Trans-Retinoic Acid (ATRA)–Induced Craniofacial Development of Murine Embryos Using In Vivo Proton Magnetic Resonance Spectroscopy

Feifei Qin1, Zhiwei Shen2, Lihong Peng1, Renhua Wu2, Xiao Hu3, Guishan Zhang2, Shijie Tang1*

1 Cleft Lip and Palate Treatment Center, Second Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong Province, People’s Republic of China, 2 Department of Medical Imaging, Second Affiliated Hospital, Shantou University Medical College, Shantou, Guangdong Province, People’s Republic of China, 3 Department of Plastic and Burn Surgery, Guangzhou Red Cross Hospital, Guangzhou, Guangdong Province, People’s Republic of China

Abstract

Aim: To characterize the abnormal metabolic profile of all-trans-retinoic acid (ATRA)–induced craniofacial development in mouse embryos using proton magnetic resonance spectroscopy (1H-MRS).

Methods: Timed-pregnant mice were treated by oral gavage on the morning of embryonic gestation day 11 (E11) with all-trans-retinoic acid (ATRA). Dosing solutions were adjusted by maternal body weight to provide 30, 70, or 100 mg/kg RA. The control group was given an equivalent volume of the carrier alone. Using an Agilent 7.0 T MR system and a combination of surface coil coils, a 3 mm × 3 mm × 3 mm 1H-MRS voxel was selected along the embryonic craniofacial tissue. 1H-MRS was performed with a single-voxel method using PRESS sequence and analyzed using LCModel software. Hematoxylin and eosin was used to detect and confirm cleft palate.

Result: 1H-MRS revealed elevated choline levels in embryonic craniofacial tissue in the RA70 and RA100 groups compared to controls (P<0.05). Increased choline levels were also found in the RA70 and RA100 groups compared with the RA30 group (P<0.01). High intra-myocellular lipids at 1.30 ppm (IMCL13) in the RA100 group compared to the RA30 group were found (P<0.01). There were no significant changes in taurine, intra-myocellular lipids at 2.10 ppm (IMCL21), and extra-myocellular lipids at 2.30 ppm (EMCL23). Cleft palate formation was observed in all fetuses carried by mice administered 70 and 100 mg/kg RA.

Conclusions: This novel study suggests that the elevated choline and lipid levels found by 1H-MRS may represent early biomarkers of craniofacial defects. Further studies will determine performance of this test and pathogenetic mechanisms of craniofacial malformation.

Introduction

Craniofacial morphogenesis, an intricate developmental process, begins with the synchronized development of head primordia, which involves several organizing centers located in the neural ectoderm, axial mesendoderm, and the cranial neural crest [1]. The differentiation and spatial patterning of these tissues must occur before they can be successfully integrated [2]. Genetic disorders, environmental insults, or the combination of both can result in craniofacial malformations [3]. Craniofacial malformations are involved in three fourths of all congenital birth defects in humans [2]. Cleft lip and palate (CLP) is the most common birth defect in human craniofacial development, causes considerable morbidity to affected children, and imposes a substantial financial risk and a concomitant societal burden for families [4]. Defects arise early in embryological development, and have a complex etiology which has limited the identification of specific etiologic factors [5,6]. Maternal conditions during pregnancy appear to play an important role in the formation of CLP, and vitamin deficiency and teratogens may increase risk for oral clefts [7–9].

All-trans retinoic acid (RA), an endogenous metabolite of vitamin A, is required for normal pattern formation during embryogenesis [10]. Conversely, abnormally high concentrations in both experimental animals and humans result in fetal malformations, including cleft palate [10,11]. In murine embryos, all-trans RA has been shown to produce craniofacial malformations when treatment occurs between embryonic day 11 (E11) and
E14.5. A single 100 mg/kg dose of all-trans RA to mice bearing E11 embryos has been shown to result in a 90–100% malformation frequency in mouse embryos [12].

Current strategies to study orofacial defects focus on related genotype and transcription factors, which only reveal part of what might be happening in a cell [13,14]. Metabolism reflects the complex molecular interactions occurring in biological systems, and can be a good measure to understand the pathophysiology of craniofacial malformations [15].

Proton magnetic resonance spectroscopy ($^1$H-MRS) is a versatile technique that can be used for measurement of metabolite levels and chemical reaction rates, and studies of small molecular metabolites of the craniofacial structure and the development of craniofacial tissue. To test this prediction, we first demonstrated the relationship between the changes in endogenous small molecular metabolites of maternal plasma and the incidence of cleft palate in fetuses [22]. However, there is no literature on the metabolite characteristics of craniofacial morphogenesis. In this study, we predicted that $^1$H-MRS could identify the metabolic consequences of maternal environmental changes during pregnancy and illustrate the relationship between changes in maternal environment and development of craniofacial tissue. To test this prediction, we first assessed the feasibility of undertaking $^1$H MRS of craniofacial tissue in vivo, and then used $^1$H-MRS to characterize metabolites in fetal craniofacial tissue within pregnant mice induced by RA to trigger cleft palate formation in the embryos. The analyses demonstrated the relationship between the changes in endogenous small molecular metabolites of the craniofacial structure and the incidence of cleft palate in embryos.

**Materials and Methods**

**Ethics**

This study was approved ethically by the Animal Ethics Committee of Shantou University Medical College.

**Animal Husbandry**

Kunming (KM) mice purchased from the Medical Animal Center of Medical College of Shantou University (Guangzhou, China) were housed in the Transformation Center in the Second Affiliated Hospital of Shantou University. They were maintained under a 12/12-hour light/dark cycle, with standard food and tap water ad libitum. The female mice were mated with males with similar weights and ages. One virgin female mouse was assigned randomly to a single male mouse. Presence of a vaginal plug was assessed after overnight mating, and gestational stage was estimated by defining the morning of that day as embryonic gestation day (E) 0.5.

**Drug administration**

Pregnant mice (n = 19) were randomly divided into four groups (three experimental groups and one control group). To evaluate the in vivo effect of exogenous RA, a single oral gavage of 30, 0 and 100 mg/kg RA suspended in 200 μl of sesame oil was administered to pregnant females at E11. All work with RA was conducted under dim yellow light to prevent photo-oxidation. Controls were treated with the equivalent amount of the carrier according to their weight.

**In vivo MRI studies**

MRI experiments were performed with a 7.0 T animal imaging system (Agilent, 7T/160/AS, U.S.A) equipped with a 95/63 mm quadrature birdcage coil for transmitting and receiving radio frequency signal. Mice were maintain anesthetized with isoflurane (3% for induction, 1–2% for maintenance, Abbott Laboratories Ltd, U.K.), which was mixed with oxygen (1 liter/min) and delivered through a nasal mask, allowing for spontaneous respiration. Once anesthetized, the animals were placed in a supine position on the center of the horizontal bore magnet for MRI/MRS scanning. Body temperature was maintained at approximately 35–37°C using a plastic membrane.

Three planes location imaging was first acquired with a gradient echo sequence for abdominal position. Subsequently, a fast spin echo multi-slice (fsmse) T2-weighted imaging in axial and sagittal position was acquired with the following parameters: field of view = 23 mm × 19 mm, matrix size = 256 × 256, repetition time (TR) = 2000 ms, effective echo time (TE) = 31.58 ms, slice thickness = 2 mm, slice gap = 0.5 mm, and acquisition time = 4 min 20 seconds.

**$^1$H-MRS**

A PRESS pulse sequence (TE/TR 144/1500 ms, 96 averages) with VAPOR water suppression was used for $^1$H-MRS acquisition. A 3 × 3 × 3 mm voxel of interesting (VOI) was located on the craniofacial region of the embryo. Voxel selection was confirmed to be limited to within the craniofacial region, using the range of orthogonal fast spin echo slices. Outer volume suppression was used around the voxel to further prevent any non-craniofacial contaminant signals. A manual shim over the second-order ge$^3$ shim automatic shim was applied over the selected voxel to counter any local inhomogeneities in the magnetic field. In our experience, the craniofacial unit does not significantly move out with our selected voxel dimensions during either maternal breathing, or fetal motion. The resulting raw spectral data were exported to an external workstation and MRS analysis was used to assess the craniofacial metabolism.

**Data analysis**

Lipid and choline were quantified using the LCMModel software package (Version 6.3-1B, LCMODEL Inc. CA). The quantification algorithm of the LCModel applies linear combinations to calculate the best fit of the experimental spectra to the model spectra. In this study, a special type of ‘muscle-5’ was used for muscle spectra analysis. The metabolite resonance area to the unsuppressed water resonance area was calculated in the same voxel by LCModel. The tissue water concentration served as the internal standard, was estimated as 42,223 mmol/L. Absolute concentrations of choline, intra-myocellular lipid (IMCL) were acquired with T1 and T2 relaxation effects correction.

The spectra were inspected for residuals and large artefacts in the spectral region of interest. In order to avoid any bias towards high concentrations, the data were discarded if the reported signal-
to-noise ratio (SNR) of spectra from LCModel was less than 5, or if the standard deviation (SD) of a metabolite was more than 20%. The data were also discarded if shown as missing values by boxplot.

Histological sections

Pregnant females (n = 19) were sacrificed by cervical dislocation and embryos (n = 211) were harvested at E17.5. At the same time, a stereomicroscope was used to determine the number of fetuses and gross malformations. After removal of the mandibles, embryonic palates were calculated using stereomicroscope (10×) and divided by morphology in four groups. Target palates were processed into paraffin wax. Histological sections of embryonic palates were cut and stained with haematoxylin and eosin (HE).

Statistical analysis

All data were presented as a mean ± standard deviation (SD). Statistical significance was calculated using Mann-Whitney Test and was accepted at P≤0.05. All analyses were performed using SPSS software (version 16.0, IBM SPSS Statistics, Inc, United States).

Results

Magnetic Resonance Imaging (MRI)

Using a fast spin-echo MRI sequence, high resolution MR images of E14.5 mouse embryos could be acquired. Figure 1A represents an in vivo coronal T2-weighted MR imaging of a pregnant mouse harboring E14.5 embryos, following treatment with RA at 70 mg/kg. Hyperintense regions were observed in the imaging. There were parts of or no embryos in the hyperintense regions. VOI = 3.0×3.0×3.0 mm³. C. In vivo proton magnetic resonance spectroscopy (¹H-MRS) obtained from the control and three experimental groups after RA treatment. Resonances were readily identified by the LCModel software. 1. Taurine; 2. Choline; 3. Creatine; 4. Extramyocellular lipids (EMCL23); 5. Intramyocellular lipids (IMCL21); 6. IMCL13.

doi:10.1371/journal.pone.0096010.g001

Proton Magnetic Resonance Spectroscopy (¹H-MRS)

In vivo localized ¹H magnetic resonance spectra were obtained from the control and three experimental groups after RA treatment. A 3 mm×3 mm×3 mm volume of interest (VOI) was used in every fetus. A typical set of in vivo ¹H-MR spectra

Figure 1. MRI and ¹H-MRS of mouse fetuses. A. Magnetic resonance imaging (MRI) of E14.5 mouse embryos at a dose of 70 mg/kg RA. Volumes of interest (VOI) = 3.0×3.0×3.0 mm³. B. MRI of E14.5 mouse embryos at a dose of 100 mg/kg RA. Hyperintense regions were observed in the imaging. There were parts of or no embryos in the hyperintense regions. VOI = 3.0×3.0×3.0 mm³. C. In vivo proton magnetic resonance spectroscopy (¹H-MRS) obtained from the control and three experimental groups after RA treatment. Resonances were readily identified by the LCModel software. 1. Taurine; 2. Choline; 3. Creatine; 4. Extramyocellular lipids (EMCL23); 5. Intramyocellular lipids (IMCL21); 6. IMCL13.
Figure 2. The boxplot from 1H-MRS of embryonic craniofacial tissues’ metabolite concentrations. The boxplot from 1H-MRS shows quantification of IMCL13, choline, taurine, IMCL21, EMCL23 concentrations in embryonic craniofacial tissues of pregnant mice. Values are mean ± standard deviation (SD). Metabolite concentrations were compared respectively. *Significant difference compared to control (P<0.05); ±Significant difference compared to RA30 (P<0.05).

doi:10.1371/journal.pone.0096010.g002

acquired from the craniofacial tissues in each group is shown in Figure 1C. Resonances were readily identified by the LCModel software. The regions of the significant metabolite signals usually ranged from δ 0.8–3.3 ppm, including lactate (δ 1.32 ppm), IMCL13 (intra-myocellular lipids) (δ 1.30 ppm), IMCL21 (δ 2.10 ppm), EMCL23 (extra-myocellular lipids) (δ 2.30 ppm), total choline (δ 3.19 ppm), total creatine (δ 3.04 ppm), and taurine (δ 3.43 ppm).

1H-MR spectroscopy revealed that compared with the control group, elevated choline levels (μmol/L) were observed in embryonic craniofacial tissues in the RA70 group (11.51±1.89 for RA70, n=14 vs. 9.30±1.66 for control, n=10, Z =−2.342, P =0.019) and RA100 group (12.04±1.91 for RA100, n=11 vs. 9.30±1.66 for control, n=10, Z =−2.958 P =0.002) by 1H-MR spectroscopy. An increase in choline levels was also found in both RA70 and RA100 groups compared with the RA30 group (12.04±1.91 for RA100, n=11 vs. 9.27±1.85 for RA30, n=9, Z =−2.621, P =0.007; 11.51±1.89 for RA70, n=14 vs. 9.27±1.85 for RA30, n=9, Z =−2.268, P =0.023). High levels of IMCL13 (μmol/L) in RA100-treated mice compared to RA30 were found (71.37±11.14 for RA30, n=9 vs. 95.84±16.22 for RA100, n=14, Z =−3.024, P =0.002). There were no significant changes in taurine, IMCL21, and EMCL23 (Table 1). Figure 2 shows a boxplot of the metabolites in every group.

Incidence of Cleft Palate in Four Groups

Nineteen KM pregnant mice were examined, and 211 embryos were collected, including 156 embryos from RA-treated group, and 55 embryos from the control group (Table 2). Each pregnant mouse had multiple embryos. There was at least one CP embryo in each pregnant mouse in the RA treatment group, while there were no CP embryos in the control group. The incidence of CP in the RA70 and RA100 treatment groups was 100%, and the incidence of CP in the RA30 group was 40%.

The morphology and histology were examined (Figure 3). “A” and “C” show fusion of the palate shelves, while “B” and “D” show a failure of the palate shelves to fuse.

| Metabolite | Control | RA30 | RA70 | RA100 |
|------------|---------|------|------|-------|
| IMCL13     | 93.90±37.55 | 71.37±11.14 | 89.86±26.03 | 95.84±16.22 |
| Choline    | 9.30±1.66 | 9.27±1.85 | 11.51±1.89 | 12.04±1.91 |
| Taurine    | 25.71±4.20 | 21.95±3.41 | 25.34±6.48 | 26.47±6.82 |
| IMCL21     | 51.04±14.47 | 53.48±21.53 | 56.48±10.59 | 59.64±15.96 |
| EMCL23     | 36.19±9.26 | 34.02±1.16 | 36.34±7.81 | 37.29±10.59 |

The concentration unit of metabolites is μmol per litre (μmol/L).

Abbreviations: IMCL, intramyocellular lipids; EMCL, extramyocellular lipids. All fetuses measured at E14.5, values are mean ± standard deviation (SD).

*Significant difference compared to control (P<0.05). ±Significant difference compared to RA30 (P<0.05).

doi:10.1371/journal.pone.0096010.t001

Discussion

The aim of this study was to identify early changes in metabolite concentrations associated with RA-induced cleft palate with a view to provide biomarkers for craniofacial defects. To this end, in vivo 1H-MRS was used in the study as a noninvasive method of investigating changes in response to RA. We determined that noninvasive quantitative measurements of choline and lipid by 1H-MRS were important for the assessment of facial structures. In the current study, total Cho levels in the fetal craniofacial structures were found to increase following administration of 70 and 100 mg/kg RA. We interpret the observed increase in the levels of choline in RA-induced mice to be an effect of the disease process. The data in this study show the feasibility of measuring choline concentration in craniofacial tissue in vivo using 7.0 T MRS acquisition and quantification methods.

RA, as an important regulator of embryogenesis, regulates proliferation, differentiation, and apoptosis during the morphogenesis of embryonic structure. [11,12,23] This is a putative biological mechanism underlying RA-induced CLP. Overexposure to RA can cause congenital malformations such as CLP. Depending on the timing of exposure, excess RA might disturb all stages of palatogenesis. During shelf outgrowth, it may decrease mesenchymal proliferation and thus prevent tissue expansion. In the next stage, RA may prevent shelf elevation by affecting the ECM composition and hydration, and during the actual fusion of the shelves, it may affect epithelial differentiation and apoptosis, which precludes the formation of a continuous palate. Growth of the palate shelves depends on the survival and continued proliferation of mesenchymal cells that originate from neural crest and mesodermal cells of the first pharyngeal arch [10,24]. In the normal mouse embryo, palate shelves grow and elevate into a horizontal position and oppose in the midline by E14.5. By E17.5, the process of fusion has completely finished. It was convenient to use morphology for embryo analysis. So we chose to collect samples on E17.5 [25].

The choline peak resonating at 3.2 ppm, seen in the in vivo 1H-MRS, is from total choline and consists of phosphocholine, glycerophosphocholine, and free choline [26–29]. Choline phospholipid metabolism comprises a complex network of biosynthetic and breakdown pathways, with one or more enzymes acting per
pathway. Collectively, the MRS data presented in this study, combined with histologic analysis of craniofacial structures, supports the mechanism of action of RA. One interpretation is that RA toxicity could cause an increase in membrane precursors (phosphocholine and phosphoethanolamine) and subsequently lead to the observed increase in membrane degradation products (glycerophosphoethanolamine and glycerophosphocholine). Phosphocholine is a precursor as well as a metabolic breakdown product of the major membrane component phosphatidylcholine [30]. A high degree of membrane degradation will lead to high choline levels. The molecular and genetic alterations in craniofacial development, as well as changes in signaling pathways, act on the expression and post-translationally regulate activity levels of these enzymes, thereby generating changes in the overall choline metabolite profile. Choline-containing metabolites are associated with cell membrane phospholipid metabolism. Therefore, changes in their concentration detected using in vivo $^1$H-MRS of craniofacial tissues treated with RA are indicative of changes in cell membrane metabolism. The increase in total choline following RA treatment suggests RA causes an increase in cell membrane turnover.

In the last 10 years, the choline metabolite profile has been increasingly used as an adjunct for diagnosis of primary malignant tumors of the brain, prostate, and breast [31]. The choline peak is also thought to reflect cellular density. For instance, an increase in the choline peak is associated with an increase in membrane breakdown or turnover, myelination or inflammation and has been observed in demyelinating diseases and in tumours. Thus, the elevation is increasingly being used as an endogenous biomarker of cancers. The enzymes and pathways resulting in these distinct alterations in phosphocholine and total choline may provide novel molecular targets for specific, targeted anticancer therapies. $^1$H-

| Table 2. Comparison of the incidence of cleft palate in the embryos between four groups. |
|-----------------|----------------|----------------|----------------|----------------|
| Dam n | Total Fetus n | Death n | Cleft Palate n | Ratio (%) |
| Control | 5 | 55 | 0 | 0 | 0 |
| RA30 | 4 | 40 | 0 | 16 | 40 |
| RA70 | 5 | 61 | 2 | 59 | 100 |
| RA100 | 5 | 55 | 20 | 35 | 100 |

doi:10.1371/journal.pone.0096010.t002

Figure 3. Fusion or lack of fusion of embryonic palatal shelves. A: Fused embryonic palatal shelves. B: A failure to fuse embryonic palatal shelves. C: Fused embryonic palatal shelf in HE stain. D: A failure to fuse of embryonic palatal shelves in HE stain.

doi:10.1371/journal.pone.0096010.g003
MRS can give spectra comparable with those obtained in the present study when used on appropriately sized tumors in patients. For example, in vivo 1H-MRS has recently been successfully used in the clinic to determine total choline concentration of locally advanced breast cancer before and after neoadjuvant chemotherapy to predict response [32].

We have identified a previously unknown association between choline metabolism and RA-induced craniofacial abnormalities. To resolve the components of the total choline signal and further characterize the differences detected in vivo, we will perform high-resolution 1H-MR spectroscopy of tissue extracts in the future. Moreover, we will further study the metabolic patterns that may represent new noninvasive biomarkers and targets in the abnormal development of craniofacial structure, choline kinase mRNA and protein levels, for example.

In our present study, an increased embryonic lipid content (at 1.30 ppm) following dosing at 100 mg/kg, compared to 30 mg/kg, was observed. 1H-MRS has been successfully used to quantify lipid content, which is commonly divided into two compartments, IMCL and EMCL. While EMCL is relatively metabolically inert, IMCL can be utilized by mitochondria, making it the preferred form of lipid storage. In our study, the amount of IMCL13 significantly changed in the high dose group. Excess RA disturbs palatogenesis, which affects mesenchymal and epithelial differentiation, and apoptosis. Coincident with the onset of differentiation and apoptosis are altered lipid packing of the lipid bilayer, membrane blebbing, and decreased membrane microviscosity, which all could change the plasma membrane fluidity [33]. Another mechanism could involve an increase in the amount of fatty acids with the lipid bilayer. Thus, the complex process results in large lipid resonances (at 1.30 ppm) by 1H-MRS in vivo.

This study confirmed the feasibility of RA-induced animal model again. Normally, the incidence of cleft palate in KM natural mice is zero. We injected sesame oil in control samples in order to keep the same stimulating circumstances as in the RA-induced group. Regarding cell membrane turnover and cell proliferation and apoptosis, a significant effect is detected after administration of a 70 mg/kg dose of RA. A 100 mg/kg dose also shows the same change, but proved to be too toxic for the mice by MRI and anatomy, and the 30 mg/kg dose did not cause malformation in all fetuses. Hence, the rate of CLP as assessed by this work appears consistent with the results of all earlier study [12], that doses of 70 mg/kg or higher induce craniofacial malformation.

To our knowledge, this is the first report of in vivo 1H-MR spectroscopy for craniofacial development and the first report in which quantitative choline and lipid measurements are made by 1H-MRS. However, there is considerable individual variation in the associations. In particular, the assessment of individual treatment responses in vivo may benefit from combining with 1H-MRS. These promising findings were obtained in a small group of mice, and thus, a large study may also provide information about the possibility of using spectroscopy to predict craniofacial malformation and determine therapeutic responses. Moreover, MRS can also lead to new hypotheses regarding pathogenetic mechanisms and to new insights and a challenging new area in the study of craniofacial malformation in the future.

Acknowledgments
We thank Shu Ye from University of London, London, UK and Stanley Lin from Shantou University Medical College for revising this manuscript.

Author Contributions
Conceived and designed the experiments: FFQ ZWS XH SJT. Performed the experiments: FFQ ZWS LHP GSZ. Analyzed the data: FFQ ZWS. Contributed reagents/materials/analysis tools: RHW SJT. Wrote the paper: FFQ ZWS LHP SJT.

References
1. Hu D, Helms JA (1999) The role of sonic hedgehog in normal and abnormal craniofacial morphogenesis. Development 126: 4873–4884.
2. Chai Y, Maxon RE Jr (2006) Recent advances in craniofacial morphogenesis. Dev Dyn 235: 2353–2357.
3. Wu T, Schweinder H, Rucinski I, Murray JC, Marazita ML, et al. (2014) Evidence of gene-environment interaction for two genes on chromosome 4 and environmental tobacco smoke in controlling the risk of nonsyndromic cleft palate. PLoS One 9: e80085.
4. Wehby GL, Cassell CH (2010) The impact of orofacial clefts on quality of life and healthcare use and costs. Oral Dis 16: 3–10.
5. Beaty TH, Murray JC, Marazita ML, Munger RG, Rucinski I, et al. (2010) A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4. Nat Genet 42: 525–529.
6. Dixon MJ, Marazita ML, Beaty TH, Murray JC (2011) Cleft lip and palate: understanding genetic and environmental influences. Nat Rev Genet 12: 167–176.
7. Little J, Cardy A, Munger RG (2004) Tobacco smoking and oral clefts: a meta-analysis. Bull World Health Organ 82: 213–218.
8. Wehby GL, Murray JC (2010) Folic acid and orofacial clefts: a review of the evidence. Oral Dis 16: 11–19.
9. Murray JC (2002) Gene/environment causes of cleft lip and/or palate. Clin Genet 61: 248–256.
10. Ackerman MM, Zhou H, Carles CE, Wagener FA, Von den Hoff JW (2011) Vitamin A and clefting: putative biological mechanisms. Nutr Rev 69: 615–624.
11. Cuero R, Valencia G, Chaudhuramala RA, Covarrubias L (2002) Programmed cell death is required for palate shelf fusion and is regulated by retinoic acid. Dev Biol 245: 145–156.
12. Campbell JL, Jr., Smith MA, Fisher JW, Warren DA (2004) Dose-response for retinoic acid-induced forelimb malformations and cleft palate: a comparison of computerized image analysis and visual inspection. Birth Defects Res B Dev Reprod Toxicol 71: 289–295.
13. Jugessur A, Skare O, Lie RT, Wilcox AJ, Christensen K, et al. (2012) X-linked genes and risk of orofacial clefts: evidence from two population-based studies in Scandinavia. PLoS One 7: e39240.
14. Ross AP, Mansilla MA, Cho Y, Helninski S, Sturm R, et al. (2013) A mutation in mouse Pak1p1 causes orofacial clefting while human PAK1P1 maps to 6p24 translocation breaking points associated with orofacial clefting. PLoS One 8: e93033.
15. Gomez-Casati DF, Zanor MI, Basi MV (2013) Metabolomics in plants and humans: applications in the prevention and diagnosis of diseases. Biomed Res Int 2013: 792527.
16. Lodi A, Ronen SM (2011) Magnetic resonance spectroscopy detectable metabolic fingerprint of response to antineoplastic treatment. PLoS One 6: e20155.
17. Story L, Damodaram MS, Allopp JM, McGuinness A, Wylezinska M, et al. (2011) Proton magnetic resonance spectroscopy in the fetus. Eur J Obstet Gynecol Reprod Biol 158: 3–8.
18. van der Graaf M (2010) In vivo magnetic resonance spectroscopy: basic methodology and clinical applications. Eur Biophys J 39: 527–540.
19. Castillo M, Kwock I, Mukherji SK (1996) Clinical applications of proton MR spectroscopy. AJNR Am J Neuroradiol 17: 1–15.
20. Nicholson JK, Holmes E, Koversa M, Darzi AW, Takats Z, et al. (2012) Metabolic phenotyping in clinical and surgical environments. Nature 491: 384–392.
21. Conti F, Manganaro M, Micchelli A (2006) [Metabolomics and medical practice]. Clin Ter 157: 549–552.
22. Zhou J, Xu B, Shi B, Huang J, He W, et al. (2011) A metabolomic approach to analyze the dexamethasone-induced cleft palate in mice. J Biomed Biotechnol 2011.
23. Yu Z, Han J, Liu J, Xiao Y, Zhang X, et al. (2006) Apoptosis induced by aRia in MEFPl cells is mediated through activation of caspase and RAR. Toxicol Sci 93: 504–509.
24. Murray JC, Schutte BC (2004) Cleft palate: players, pathways, and pursuits. J Clin Invest 113: 1676–1678.
25. Okano J, Suzuki S, Shiota K (2007) Involvement of apoptotic cell death and cell cycle perturbation in retinoic acid-induced cleft palate in mice. Toxicol Appl Pharmacol 221: 42–56.
26. den Heijer T, Siemons PE, Prins ND, Hofman A, Koudstaal PJ, et al. (2006) MR spectroscopy of brain white matter in the prediction of dementia. Neurology 66: 540–544.
27. Bhutzaj JK, Wurtman RJ (1983) Choline and cholinergic neurons. Science 221: 614–620.
28. Qian J, Herrera JJ, Narayana PA (2010) Neuronal and axonal degeneration in experimental spinal cord injury: in vivo proton magnetic resonance spectroscopy and histology. J Neurotrauma 27: 599–610.

29. Denison FC, Semple SI, Stock SJ, Walker J, Marshall I, et al. (2012) Novel use of proton magnetic resonance spectroscopy (1HMRS) to non-invasively assess placental metabolism. PLoS One 7: e42926.

30. Begley JK, Redpath TW, Bolan PJ, Gilbert FJ (2012) In vivo proton magnetic resonance spectroscopy of breast cancer: a review of the literature. Breast Cancer Res 14: 207.

31. Penet MF, Gadiya MM, Krishnamachary B, Nimmagadda S, Pomper MG, et al. (2013) Metabolic signatures imaged in cancer-induced cachexia. Cancer Res 71: 6946–6956.

32. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, et al. (2004) Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy—a pilot study at 4 T. Radiology 233: 424–431.

33. Shih CM, Ko WC, Yang LY, Lin CJ, Wu JS, et al. (2005) Detection of apoptosis and necrosis in normal human lung cells using 1H NMR spectroscopy. Ann N Y Acad Sci 1042: 488–496.